The Journal of Allergy and Clinical Immunology: In Practice
Volume 8, Issue 7, July–August 2020, Pages 2379-2383
Original ArticleClinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema—A Long-Term Survey
Under a Creative Commons license
open access
Key words
Hereditary angioedema
Pediatric patients
Clinical symptoms
Safety
Plasma-derived C1-inhibitor
Inherited risk factors for thromboembolism
Anti-C1-inhibitor antibodies
Abbreviations used
C1-INH
C1-inhibitor
C1-INH-HAE
Hereditary angioedema with C1-inhibitor deficiency
HAE
Hereditary angioedema
ITP
Intermittent prophylaxis
LA
Lupus anticoagulant
pdC1-INH
Plasma-derived C1-inhibitor concentrate
STP
Short-term prophylaxis
Cited by (0)
No funding was received for this work.
Conflicts of interest: H. Farkas has received honoraria and travel grants from CSL Behring, Shire, Swedish Orphan Biovitrum, and Pharming; and/or served as a consultant for these companies and has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, and Shire. K. V. Kőhalmi has received honoraria and travel grants from CSL Behring and Shire and has participated in clinical trials of BioCryst, CSL Behring, Pharming, and Shire. L. Varga has received travel grants from CSL Behring and Shire. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.
© 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.